01 4Atripla
02 4Complera/Eviplera
03 3Stribild
04 5Truvada
05 6Vemlidy
06 10Viread
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 657
2019 Revenue in Millions : 488
Growth (%) : 35
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 269
2019 Revenue in Millions : 406
Growth (%) : -34
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 1,448
2019 Revenue in Millions : 2,813
Growth (%) : -49
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 349
2019 Revenue in Millions : 600
Growth (%) : -42
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 185
2019 Revenue in Millions : 243
Growth (%) : -24
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 196
2019 Revenue in Millions : 369
Growth (%) : -47
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 814
2020 Revenue in Millions : 657
Growth (%) : 24
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 258
2020 Revenue in Millions : 269
Growth (%) : -4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 371
2020 Revenue in Millions : 1,448
Growth (%) : -74
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 145
2020 Revenue in Millions : 349
Growth (%) : -58
LOOKING FOR A SUPPLIER?